Raymond James analyst Andrew Cooper downgraded CareDx to Market Perform from Strong Buy without a price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CDNA:
- Billing and coding document looks ‘clearly negative’ for CareDx, says Stephens
- CareDx price target lowered to $25 from $28 at BTIG
- CareDx price target lowered to $26 from $32 at Craig-Hallum
- CareDx reports Q4 adjusted EPS (7c), consensus (9c)
- CareDx to present cellular transplant progress at Tandem Meetings